IL17A and pancreatic neoplasm: Clinical findings of IL-17RB upregulation in PDAC patients as well as the positive correlation of IL-17 signaling blockade with tumor regression in mice provide additional support for the protumorigenic effect of IL-17 on pancreatic cancer prognosis [43].